Abstract

Transcatheter aortic valve replacement (TAVR) for severe symptomatic aortic stenosis is the standard of care in inoperable patients and an alternative to surgical aortic valve replacement in high-risk operable patients. Several issues affecting outcomes with implantation of the first-generation TAVR devices remain unresolved, including neurological and vascular complications, atrioventricular conduction abnormalities, and paravalvular aortic regurgitation. New-generation TAVR devices are currently in different stages of clinical development and evaluation. Modifications in the new devices include the ability to reposition the valve before final deployment, features to reduce paravalvular leakage, lower-profile delivery systems, and cerebral protection devices. The purpose of this manuscript is to give an update on the new-generation transcatheter valvular technologies, focusing on the unique features and describing the initial clinical experience for each device.

Key Words:
New devices • Transcatheter aortic valve replacement • Transcatheter aortic valve implantation • TAVR • Transcatheter aortic valve implantation (TAVI)

Introduction

Transcatheter aortic valve replacement (TAVR) has emerged as a treatment option for inoperable or high-risk surgical patients with severe aortic stenosis (AS) [1, 2]. Since the first-in-human TAVR procedure performed by Professor Alan Cribier in 2002 [3], more than 100,000 TAVR procedures have been performed worldwide. Considerable experience has been acquired with the two first-generation TAVR devices: the balloon-expandable Edwards SAPIEN/SAPIEN XT (Edwards Lifesciences, Irvine, CA, USA) and the self-expandable Medtronic CoreValve (Medtronic, Minneapolis, MN, USA). Randomized clinical trials comparing this technology in high risk patients against surgery or medical therapy, as well as multicenter national registries have shown high success rate and increasingly predictable results [2, 4–7].

Clinical outcomes of TAVR have improved over the years, mainly as a result of appropriate patient selection, growing operator experience, and major technical refinements. Nonetheless, the rate of complications related to TAVR remains substantial. A recent meta-analysis found the risk of periprocedural stroke following TAVR to be 1.5% and a 30-day stroke/transient ischemic attack (TIA) rate of 3.3%. Paravalvular aortic regurgitation (PV-AR) after TAVR, including small or trace leaks is quite common (incidence 50–85%), with the vast majority of cases graded as mild or less [8, 9]. Increasing severity of PV-AR following TAVR have been directly associated with increased mortality [2, 7, 9, 10]. Other issues affecting short and long term outcome following TAVR include hemorrhagic and vascular complications, atrioventricular conduction abnormalities, valve malpositioning and coronary obstruction [11]. To overcome these obstacles, and in order to enable the utilization of TAVR for lower risk populations, new-generation TAVR devices...
are currently in early stages of clinical evaluation. Modifications in these new devices include the ability to reposition and recapture the valve before final deployment, features intended to minimize PV-AR, and the introduction of low-profile delivery systems. The present manuscript provides an update on the new-generation transcatheter valvular technologies, focusing on the unique features and describing the initial clinical experience for each device.

**Edwards Lifesciences SAPIEN 3**

The SAPIEN 3 (S3) valve (Edwards Lifesciences, Irvine, CA, USA) is a new balloon-expandable valve that can be implanted using the transfemoral, trans-subclavian, transapical, or transaortic approaches. It incorporates features intended to reduce vascular complications, increase paravalvular sealing, and enhance ease of positioning [12]. This device is composed of a radiopaque, cobalt chromium frame and a trileaflet bovine pericardial tissue valve (Figures 1, 2 and Movie 1). It incorporates a stent and leaflet design that allows for crimping to a reduced profile as compared with the predicate SAPIEN and SAPIEN XT devices. The inflow of the S3 valve is covered by an internal polyethylene terephthalate skirt similar to the earlier SAPIEN XT device. However, the S3 incorporates an additional outer polyethylene terephthalate cuff to enhance paravalvular sealing thus reducing PV-AR. This sealing cuff has no filling and
functions like a parachute by bulging outward [13]. The Edwards Commander transfemoral delivery system (Edwards Lifesciences, Irvine, CA, USA) has lower profile and higher flexibility compared to the currently used NovaFlex system (Edwards Lifesciences, Irvine, CA, USA). It contains a fine adjustment wheel that permits a precise positioning of the crimped valve in the aortic annulus without unnecessary pushing or pulling. A central radiopaque marker in the balloon also assists in valve positioning. The system uses a 14-F expandable eSheath (Edwards Lifesciences, Irvine, CA, USA), that intend to reduce the potential for arterial injury during introduction but can transiently expand to accommodate passage of the compressed valve and then return to its lower profile diameter.

Recently, the 30-day outcomes of 150 patients that underwent S3 valve implantation in Europe and Canada were published [14]. A transfemoral approach was chosen in 64.0% and transapical/direct aortic in the remainder. At 30 days, PV-AR was none to mild in 96.4% and moderate in 3.5%. No patient had severe regurgitation. Transfemoral implantation was associated with low 30-day mortality (2.1%) and no disabling stroke. Alternative access was associated with higher rates of 30-day mortality (11.6%) and stroke (5.6%). This device is available in 20-, 23-, 26-, and 29-mm sizes and is expected to facilitate fully percutaneous implantation in a broader range of patients with the potential for more accurate positioning and less PV-AR. The initial 30-day outcomes of the PARTNER II S3 Trial (n=1,659) have demonstrated 30-day mortality rate of 2.2% for the overall high-risk cohort and 1.1% for the intermediate-risk cohort. Moderate or higher PV-AR at 30-days was present in 2.9% of the high-risk patients and 4.2% of the intermediate-risk patients [15]. Since June 2015, Sapien 3 has a U.S. Food and Drug Administration (FDA) approval.

Currently ongoing trials with SAPIEN 3 valve are the PARTNER II trial (Placement of aortic transcatheter valves; ClinicalTrials.gov Identifier: NCT01314313) and the safety and performance study of the Edwards SAPIEN 3 transcatheter heart valve trial (NCT01808287).

**Medtronic CoreValve Evolute / Evolute R**

The Evolute (Medtronic, Minneapolis, MN, USA) 23mm valve was the first next-generation CoreValve device (Figure 3). It is indicated for small (18–20 mm) aortic annuli and designed to be fully repositionable, resheathable and recapturable [16]. It has a Conformité Européenne (CE) mark for valve-in-valve implantations since 2013 and was previously described for this indication in case reports [17, 18].

The newly designed CoreValve Evolute R (Medtronic, Minneapolis, MN, USA) is a low-profile system that retains many of the characteristics of its predecessors: radiopaque self-expanding nitinol support frame, supra-annular trileaflet porcine pericardial leaflets, and porcine pericardium fabric skirt [19]. The cell geometry and frame of this valve have been redesigned to optimize frame interaction with the native anatomy, to improve conformability to the aortic annulus and reduce PV-AR. The inflow has more consistent radial force across the sizing spectrum, and the outflow has been shortened and reshaped to provide improved alignment between valve housing and the native sinus. The valve leaflets are routinely treated with alpha-amino oleic acid to impede calcium deposition. The new EnVeo R deliv-
The bioprosthetic aortic valve implant comprises three bovine pericardial leaflets supported on a braided nitinol frame (Figure 4). An outer adaptive seal is designed to minimize PV-AR. Currently, the valve is available in 23- and 27-mm sizes; an additional valve size of 25 mm is anticipated. The transfemoral delivery system is 18 Fr compatible. The delivery handle incorporates a simple, ergonomic design that enables a controlled, predictable, and accurate deployment. If the initial deployment is suboptimal, the device can be subtly advanced or retracted as needed or even completely retracted into the delivery sheath at any time prior to the final release. The valve functions early in deployment, providing hemodynamic stability for the patient and enabling the operator to complete the delivery process in a controlled and considered fashion.

The multicenter REPRISE II study has been recently published [22]. It examined transfemoral implantation of 23- or 27-mm Lotus valve in 120 patients with severe AS. The valve was successfully implanted in all patients, with no cases of valve embolization or additional valve implantation. All repositioning (n= 26) and retrieval (n=6) attempts were successful; 34 patients (28.6%) received a permanent pacemaker. The Mean gradient improved from 46.4± 15 mm Hg to 11.5±5.2 mm Hg. At 30 days, the mortality rate was 4.2%, and the rate of disabling stroke was 1.7%; one patient had moderate PV-AR, whereas none had severe PV-AR. CE mark approval for Lotus valve system was obtained in 2013.

Four clinical trials evaluating efficacy and safety of Lotus valve implantation are currently ongoing (ClinicalTrials.gov Identifier: NCT02202434, NCT02031302, NCT01627691, NCT01383720).

**Direct Flow Medical Valve**

The Direct Flow Medical aortic valve (Direct Flow Medical, Santa Rosa, CA, USA) is a nonmetallic percutaneous valve with an inflatable ring cuff frame designed to encircle and capture the native valve annulus, thereby ensuring anchoring of the bioprosthesis and minimizing potential PV-AR, dislodgement or migration [23] (Figure 5). The tricuspid bovine pericardial valve is attached to a polyester catheter (Medtronic, Minneapolis, MN, USA) features a complete redesign of the AccuTrak system (Medtronic, Minneapolis, MN, USA) that is currently employed for CoreValve implantation. The EnVeo R catheter with InLine sheath (Medtronic, Minneapolis, MN, USA) is a 14 Fr-equivalent system that can deliver the transcatheter heart valve without the requirement for a separate introducer sheath. The modified valve capsule allows the valve to be fully recaptured and repositioned during deployment. The valve is available in 23, 26 and 29 mm sizes. A report of the initial results of implantation of this device in 60 patients revealed no case of mortality at 30-days and 3.4% of moderate or higher PV-AR [20]. As of June 2015 Evolut R has a U.S. FDA approval.

Currently ongoing trials with Evolute R valve are the Medtronic CoreValve Evolute R CE mark clinical study (ClinicalTrials.gov Identifier: NCT01876420) and the Medtronic CoreValve Evolute R U.S. clinical study (NCT02207569).

**Boston Scientific Lotus**

The Lotus Valve System (Boston Scientific, Natick, MA, USA) comprises a bioprosthetic aortic valve implant and a catheter-based delivery system for introduction and delivery of the valve implant [21].
Linx anticalcification technology and a porcine pericardial sealing cuff [25, 26] (Figures 6 and 7). The outflow portion of the stent frame incorporates three retention tabs, which secure the crimped valve to the delivery system [26]. The transfemoral delivery catheter consists of a soft tapered nose cone, an 18 Fr capsule that contains the compressed valve, and a 12Fr shaft. The system is designed to deliver the valve gradually, deploying it to the point of functionality while allowing for controlled recapture, followed by controlled recapture, followed by

The results of a prospective multicenter evaluation of the direct flow medical transcatheter aortic valve have been recently published [24]. One-hundred patients with severe AS underwent transfemoral implantations. Device success was 93%, all-cause mortality at 30 days was 1%, and major stroke rate was 4%. The post-implantation echocardiography results demonstrated mild or no aortic regurgitation (AR) in 99% with a mean gradient of 12.6±7.1 mm Hg and effective orifice area of 1.50±0.56 cm². The direct flow medical valve has received a CE mark at 2013.

Three clinical trials evaluating efficacy and safety of Direct Flow Medical aortic valve implantation are currently ongoing (NCT01845285, NCT02163850, and NCT01932099).

**St. Jude Medical Portico**

The trileaflet self-expanding Portico valve (St. Jude Medical, Minneapolis, MN, USA) consists of a nitinol frame, bovine pericardial leaflets processed with the Linx anticalcification technology and a porcine pericardial sealing cuff [25, 26] (Figures 6 and 7). The outflow portion of the stent frame incorporates three retention tabs, which secure the crimped valve to the delivery system [26]. The transfemoral delivery catheter consists of a soft tapered nose cone, an 18 Fr capsule that contains the compressed valve, and a 12Fr shaft. The system is designed to deliver the valve gradually, deploying it to the point of functionality while allowing for controlled recapture, followed by
either by repositioning and redeployment or by removal. Portico transaortic and subclavian delivery systems will also be available with designs similar to the transfemoral system. The 24 Fr delivery system used for transapical approach is composed of a tapered nose cone, a capsule containing the compressed valve and similarly allows repositioning of the valve if needed [27]. The Portico valve is sized according to the nominal external stent diameter at the valvular level. Currently, 23- and 25-mm devices are available for commercial use in Europe, and 27- and 29-mm devices are being evaluated in clinical trials.

First-in-human experience with Portico device included a 23-mm device implanted in 10 patients with severe AS via transfemoral approach [26]. At 30-day follow-up, echocardiographic mean transaortic gradient was reduced from 44.9±16.7 mm Hg to 10.9±3.8 mm Hg (p < 0.001), and aortic valve area (AVA) increased from 0.6±0.1 cm² to 1.3±0.2 cm² (p < 0.001). PV-AR was mild or less in 9 patients and moderate in 1 patient. There were no major strokes, major vascular complications, major bleeds, or deaths. No patient required pacemaker implantation. A case report of transapical Portico implantation has also been described [27].

Five clinical trials evaluating efficacy and safety of Portico valve implantation are currently ongoing (ClinicalTrials.gov Identifier: NCT02000115, NCT01802788, NCT01742598, NCT01493284, and NCT02088021).
Edwards Lifesciences Centera

The self-expandable CENTERA valve (Edwards Lifesciences, Irvine, CA, USA) is an ultra-low-profile valve that consists of three treated bovine pericardial tissue leaflets attached to a nitinol frame with a polyethylene terephthalate skirt intended to minimize PV-AR [28] (Figures 8 and 9). Currently, the valve is available in 23- and 26-mm sizes; an additional valve size of 29 mm is anticipated. The stent frame does not have a flared distal section that extends into the ascending aorta and therefore is shorter than that of other self-expandable valves. This facilitates self-centering and seating of the valve within the annulus, and it may also help to improve paravalvular sealing with minimal protrusion of the valve frame into the left ventricle. The delivery system consists of a delivery catheter and a detachable, battery-powered motorized handle, which can be delivered by the transfemoral or subclavian approaches. The capability to re-sheath and reposition in situ prior to complete valve deployment is an expected feature and may reduce the risk of valve malposition or embolization. The delivery system is compatible with a 14 Fr eSheath. The dynamic expansion mechanism of the eSheath allows for transient sheath expansion during valve delivery. Immediately after the valve passes through the sheath, the sheath return to a low-profile diameter thus reducing the time the access vessel is expanded, and minimizing the risk of vascular trauma.

The CENTERA valve was implanted in 15 patients with symptomatic severe AS via transfemoral (n=11) or transaxillary (n=4) approaches [29]. All 15 implantations were successful. Post-procedurally, AVA increased from 0.7±0.1 cm² to 1.6±0.4 cm² (p < 0.01) and mean trans-aortic gradient decreased from 36.3±14.2mmHg to 10.6±5.4mmHg (p <0.001). PV-AR at 30-day follow-up was none or trivial in 23%, mild in 69% and moderate in 8% of the patients. Survival was 87% at 30 days and 80% at 1 year, and four patients (27%) received a new permanent pacemaker.

The safety and performance study of the Edwards CENTERA self-expanding transcatheter heart valve trial is currently ongoing (ClinicalTrials.gov Identifier: NCT01808274).
JenaValve

The self-expandable JenaValve (JenaValveTechnology GmbH, Munich, Germany) consists of a full porcine root valve mounted on a low-profile nitinol stent [31] (Figure 12). In contrast to devices expanding within the aortic annulus, it relies on an active clip fixation of the native aortic valve leaflets, thereby eliminating great radial forces on cardiac and aortic structures. This allows for a short stent design that prevents coronary compromise by the native leaflets or stent struts, and that does not interfere with future coronary intervention. The unique clip fixation mechanism can provide secure anchoring to the native leaflets even in the absence of calcification and therefore may be utilized successfully for the treatment of non-calcified pure aortic regurgitation (AR) [32]. The feature of anatomically aligned positioning eliminates the need for rapid pacing during implantation. The device is delivered via transfemoral approach using a sheathless 32 Fr delivery catheter that is utilized for three-step deployment procedure. The valve is available in three different sizes (23mm, 25mm, and 27mm) for implantation in native aortic annuli ranging from 21- to 27-mm in diameter. A transfemoral JenaValve Plus is currently being developed with sim-

Venus A Valve

The Venus A Valve (Venus Medtech, Hangzhou Inc., Shanghai, China) is a self-expanding nitinol stent frame carrying a trileaflet bioprosthetic valve made of porcine pericardial leaflets (Figures 10 and 11). The delivery system is 18Fr and can be delivered sheathless by the transfemoral and transaxillary/transsubclavian approach and with a sheath for the transaortic approach [30]. The radial force of expansion for the inflow was increased early in the study, enabling a more consistent device expansion in the presence of extreme aortic valve calcification, which had been frequently observed in the treated population.

Moreover, midway in the first-in-man study, the inclusion criteria were extended to bicuspid aortic valve disease, given the frequency of cases encountered in China. Patients are treated under local anesthesia for the transfemoral and transaxillary approach and under general anesthesia for the transaortic approach. The first in-man Venus A-Valve trial is currently ongoing (ClinicalTrials.gov Identifier: NCT01683474). Recently, the initial results of Venus A valve implantation in 101 patients have been presented [30]. At 30-days, all-cause mortality was 2% and moderate-severe PV-AR rate was 6%.

Figure 11: Aortography with contrast injection of a patient with Venus A valve following TAVR.

Figure 12: The JenaValve. A self-expandable composed of a full porcine root valve mounted on a low-profile nitinol stent. A unique clip fixation mechanism provides anchoring to the native leaflets.
imilar features and an 18 Fr delivery system that is composed of three combined coaxial catheters [33].

A pivotal study for CE mark approval included transapical JenaValve implantations in 73 patients with severe AS [34]. Mean transaortic gradient was reduced post-procedurally from 40.6±15.9 mm Hg to 10.0±7.2 mm Hg, (p < 0.001), and AVA increased from 0.7±0.2 cm² to 1.7±0.6 cm² (p < 0.001) and there was no or minimal PV-AR in 86.4% of the patients. Procedural success rate was 89.6%, perioperative stroke occurred in two cases (3%) and pacemaker implantation was necessary in six patients (9.1%). Seiffert et al. have described a case series of five patients that underwent transapical implantation of a JenaValve for moderate to severe, non-calcified AR [32]. Implantation was successful in all cases without relevant remaining AR or AS. No major device- or procedure-related adverse events occurred and all patients were alive with improved exercise tolerance at 3-month follow-up. JenaValve has a CE mark for treatment of patients with AS since 2011 and for treatment of patients with non-calcified AR since 2013.

Currently ongoing trial with JenaValve is the JUPITER registry (long-term safety and performance of the JenaValve; ClinicalTrials.gov Identifier: NCT01598844).

Symetis ACURATE TA / TF

The self-expanding ACURATE TA device (Symetis SA, Ecublens, Switzerland) has been specifically developed for the transapical approach [35]. The nitinol stent frame was designed to facilitate a simple single-operator two-step implantation technique (Figures 13 and 14). Three arches are mounted at the distal edge of the stent body to stabilize the prosthesis during final deployment. The upper crown is formed by the most distal part of the stent body and is meant to embrace the native calcified leaflets. The stent commissures are well visible under fluoroscopy with a circular radiopaque appearance which facilitates anatomical rotation of the prosthesis for commissural alignment. A biological tissue valve is

**Figure 13:** The ACURATE TA valve. A self-expandable valve composed of a nitinol stent frame and a biological tissue valve mounted within the stent. A polyethylene terephthalate skirt is mounted at the intra-annular part of the stent body.

**Figure 14:** Angiography of an ACURATE TA valve.
mounted within the nitinol stent. This valve has a similar leaflet thickness to conventional surgical porcine tissue valves because the design does not require excessive “crimping” of the leaflets. To minimize PV-AR, a polyethylene terephthalate skirt is mounted at the proximal (intra-annular) part of the stent body. The delivery system is based on a sheathless concept similar in size to a 28 Fr sheath system. Valve deployment is facilitated using a simple rotational knob suitable for a single-operator technique. Until final release the system allows for reshæthing and repositioning. Three different sizes (labeled small, medium and large) are available allowing for treatment of patients presenting with an annulus diameter ranging from 20–27 mm. A transfemoral version of this device called ACURATE TF is very similar to the ACURATE TA device [36]. A 20 Fr delivery system has a flexible shaft facilitating easy tracking even in tortuous aortic anatomy. It allows a controlled three-step implantation of the prosthesis. There is also a newer transfemoral version called ACURATE neo that has a 15 Fr compatible delivery system.

The results of a first-in-human trial in 40 patients that underwent ACURATE TA implantation including 6 month follow-up have been published [35, 37]. Device success rate was 92.5%, mean transaortic gradient was reduced from 51.9 ±14.3 mm Hg to 11.9 ± 5.8 mm Hg. Thirty-day mortality was 12.5% and major stroke rate was 5%. At 6 months, only 3.3% of patients had more than mild PV-AR. Similar outcome have been published recently in a series of 62 patients [38]. A first-in-human trial in 20 patients treated with the ACURATE TF device has also been published [36]. The effective orifice area improved from 0.7 cm² to 1.8 cm² and only one patient had a grade 2 PV-AR. Procedural success rate was 95% with one case of stroke, and two pacemaker implantations at 30 days. ACURATE TA device has a CE mark obtained at 2011 and ACURATE neo device has a CE mark obtained at 2014.

**Medtronic Engager**

The Engager Aortic Valve bioprosthesis (Medtronic, Minneapolis, MN, USA) is a biological valve prosthesis composed of three leaflets cut from tissue-fixated bovine pericardium, sewn to a polyester sleeve and mounted on a compressible and self-expanding nitinol frame [39] (Figure 15). The stent assembly consists of a shaped main frame and a support frame, which are coupled together so as to form the commissural posts of the valve. Two types of sewing materials are used: polyester and expanded polytetrafluoroethylene. The valve design is intended to minimize PV-AR. The prosthesis is available in two sizes (23 mm and 26 mm) covering annulus diameters from 21 to 27 mm [40]. To achieve an anatomically correct position and to minimize the risk of coronary obstruction, the side arms fixed at the main frame of the prosthesis are designed to be placed into the sinuses of the aortic root. The valve can be repositioned before final deployment. Implantation is performed transapically with an over-the-wire delivery system comprising an introducer and a flexible delivery catheter which form one integral unit. The delivery system is composed of a 29 Fr (inner diameter) introducer and a flexible delivery catheter with a 13 Fr shaft. Engager valve has a CE mark for treatment of patients with AS since 2013.
A feasibility study with the Engager system was conducted in 10 patients [39]. All 10 patients were implanted successfully. There were no device related complications. At 30 days, one patient died from multi-organ failure. The mean aortic gradient post-procedurally was 15.6±4.9 mm Hg, and no more than a mild PV-AR was seen as assessed by echocardiography. The results of the first 61 patients enrolled in the European pivotal trial have showed all-cause mortality of 9.9% at 30 days, mean aortic valve gradient of 11.5±5.0 mm Hg, and no PV-AR greater than mild [41].

Two clinical trials evaluating efficacy and safety of the Medtronic Engager valve implantation are currently ongoing (ClinicalTrials.gov Identifier: NCT01348438, NCT01789567)

**The Helio Transcatheter Aortic Dock**

The Helio transcatheter aortic dock (Edwards Lifesciences, Irvine, CA, USA) is the first dedicated transcatheter device for the treatment of pure AR [42]. It consists of a self-expandable nitinol stent encased in polyethylene terephthalate fabric. The dock is fixed inside the aortic root and it is intended to assist in annular fixation of a standard balloon-expandable SAPIEN XT valve by incorporating and entrapping the native cusps. The currently available dock has a diameter of 25 mm, suitable for implantation with a 29 mm SAPIEN XT valve. It is intended that future devices will be compatible with a full range of balloon-expandable valves. The Helio delivery catheter is advanced through the 16 Fr eSheath over the stiff wire. The dock is then expanded within the aortic root by retracting a covering sleeve and positioned deep within the sinuses but outside the aortic valve cusps. A NovaFlex (Edwards Lifesciences, Irvine, CA, USA) delivery catheter is then advanced through the contralateral femoral sheath and a SAPIEN XT valve positioned within the dock and within the native valve. The clinical data currently available on this device is limited. In the first-in-human feasibility trial, four patients were treated successfully with a combined transfemoral-transapical approach. All of them were alive at 30 days and had no residual AR [43]. A fully percutaneous bilateral transfemoral approach is currently being evaluated.

**Cerebral Protection Devices**

Cerebrovascular events are among the most serious adverse events reported after TAVR and are associated with increased morbidity and mortality. The incidence of cerebrovascular events during the 30-
The observation that most cerebrovascular events occur within the first days after device implantation, implies that the stroke has a thromboembolic origin [44]. In order to minimize the risk of thromboembolic cerebrovascular accidents during TAVR, cerebral protection devices are currently being developed.

Embrella Embolic Deflector

The Embrella Embolic Deflector system (Edwards Lifesciences, Irvine, CA, USA) consists of an oval-shaped nitinol frame covered with a porous polyurethane membrane that is positioned at the level of the aortic arch with the purpose of deflecting embolic debris generated during TAVR procedures [45] (Figures 16 and 17). The device is inserted via the right radial or brachial approach using a 6 Fr delivery system. The frame of the device has two opposing petals that are positioned along the greater curvature of the aorta, covering the ostia of both the brachiocephalic and the left common carotid arteries. In a pilot study recently published, the Embrella Embolic Deflector system was used in 41 patients during TAVR, compared to 11 patients that underwent TAVR without embolic protection [45]. The system was successfully deployed at the level of the aortic arch in all patients with no complications. The use of the system was associated with a lower cerebral lesion volume demonstrated with diffusion weighted magnetic resonance imaging (DW-MRI) compared with the control group (p=0.003).

TriGuard

The TriGuard Cerebral Protection Device (Keystone Heart Ltd, formerly SMT Research & Development, Caesarea, Israel) is introduced via the femoral artery. The concept is similar to that of the Embrella device with some notable differences. A 9 Fr sheath is usually used for delivery and retrieval and allows additional placement of a pigtail catheter for procedural guidance. The device itself consists of a nitinol mesh and a nitinol frame with two stabilizers that anchor the device in the brachiocephalic trunk and at the inner curvature of the aortic arch [46] (Figure 18). Initial clinical experience in 15 patients demonstrated successful placement of the embolic protection device in all of them without procedural complications [47]. No patient developed new neurological symptoms except one patient who suffered from TIA two days after the procedure. DW-MRI showed 3.2 new cerebral lesions per patient, compared to 7.2 new lesions per patient in a historical control group without the device. The day period after TAVR ranges from 3% to 7%, with the majority of patients experiencing ‘major’ strokes [11].
Structural Heart Disease, August 2015

Original Scientific Article

Recently published DEFLECT III trial included 46 patients treated with TriGuard vs. 39 control patients [48]. TriGuard use was associated with greater freedom from new ischemic brain lesions (26.9 vs. 11.5%), fewer new neurologic deficits detected by the National Institutes of Health Stroke Scale (3.1 vs. 15.4%) and better performance on a delayed memory task (p=0.028).

Claret CE Pro / Montage Dual Filter System

The Montage Dual Filter System (Claret Medical Inc., Santa Rosa, CA, USA) is designed to capture embolic debris travelling to the brain in the brachiocephalic trunk and the left common carotid arteries [46]. The catheter is delivered through a 6 Fr sheath via the radial or brachial artery. The conically shaped filters consist of a nitinol frame and polyurethane laser-drilled filter membrane with 140 μm-diameter pores (Figures 19 and 20). The filter frames are radiopaque and once deployed seal against the vessel wall, allowing filtered blood to pass to the brain while trapping debris. After positioning of the first filter in the brachiocephalic trunk, the catheter is advanced further in the aortic arch under fluoroscopic guidance and the tip of the delivery system is curved towards the left common carotid artery for placement of the second filter. The safe use of the system has been demonstrated in first-in-human study, which included 40 patients [49]. Technical success rate with delivery of the proximal and distal filter was 60% for the first generation device and 87% for the second-generation device. Captured debris was documented in at least 19 of 35 implanted devices (54.3%). No procedural TIAs or strokes have occurred. Recently, the results of the CLEAN-TAVI trial were presented [50]. It is a prospective, double-blinded, randomized-controlled trial that included 100 patients. Cerebral protection device success was 96% (48/50). The number and volume of cerebral lesions as determined by DW-MRI subtraction was significantly reduced in the cerebral protection group. Two days post TAVR, neurological deficit was observed in 28% of patients in the control group compared to 13% of patients in the cerebral protection group (p=0.08).

**Conclusions**

TAVR has emerged as an established technique for the treatment of patients with symptomatic severe AS. Cumulative evidence has proven the short- and mid-term efficacy of this procedure, while improvements in implantation techniques and advances in TAVR technology have created high expectations for the future. The main challenges derived from the clinical experience with the first-generation TAVR devices were to reduce neurological and vascular complications and to minimize rates of PV-AR. The new-generation TAVR devices are currently in early clinical evaluation and have been specifically developed and designed to overcome these challenges. The features of these devices should allow the delivery catheter profile to be reduced, facilitate accurate positioning, repositioning and retrieval if needed, and reduce the incidence of significant PV-AR. New cerebral protection devices are expected to reduce clinical and sub-clinical embolic events. Although preliminary data with these new devices seem very promising, the clinical experience is still limited and more long-term data are required.
Nevertheless, continuous effort to develop, improve and clinically evaluate these devices and techniques will eventually enable safe alternative to aortic valve surgery for an increasing number of patients.

Conflict of Interest

Dr. Makkar is a consultant and has received grant support from Edwards Lifesciences Corporation, Medtronic Inc., and St. Jude Medical; and holds equity in Entourage Medical. Dr. Jilaihawi is a consultant for Edwards Lifesciences Corporation, St. Jude Medical, and Venus MedTech.

References


